louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT04745416: Clinical Characteristics of Patients With Leukemia and COVID-19
Official title: Clinical Characteristics of Patients With Hematological Cancer Diagnosed and Severe Acute Respiratory Syndrome Coronavirus 2 Infection at the Hospital de Alta Especialidad de Ixtapaluca and the Hospital General de México "Dr. Eduardo Liceaga"
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Leukemia, Acute
Covid19
Leukemia, Lymphoblastic
Lead sponsor: Hospital General de Mexico
Sponsor class: OTHER_GOV
First posted: 2021-02-09
Enrollment: 30
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients with first diagnosis of acute lymphoblastic leukemia

Brief summary: The purpose of this study is to describe the main clinical characteristics of patients with de novo acute lymphoblastic leukemia treated inside the third level hospitals converted to Coronavirus disease 2019 (COVID-19) attention for the metropolitan area of Mexico City.

Detailed description: Retrospective, observational study in patients with diagnosis of acute lymphoblastic leukemia, according to the criteria of the World Health Organization, from April 2020 to December 2020. Patients was cared for in the hematology department of the Hospital Regional de Alta Especialidad de Ixtapaluca or the Hospital General de México. Both hospitals have been assigned as Coronavirus disease 2019 (COVID-19) hospitals, limiting the access, number of outpatient visits and chemotherapy protocols.

Real-time polymerase chain reaction (RT-PCR) test for Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was performed for patients with respiratory symptoms or history of contact with suspected / confirmed cases of COVID-19 Upon having a positive RT-PCR test, patients were transferred to a respiratory isolation unit to continue their recovery. Support treatment for COVID-19 was based on local considerations.

Eligibility criteria: Inclusion Criteria:

* Patients with diagnosis of acute lymphoblastic leukemia according to the criteria of the World Health Organization.

Exclusion Criteria:

* Age less than 18 years
* Incomplete medical records

Primary outcomes:
measure: Overall survival
timeFrame: through study completion, an average of 1 year
measure: Progression free survival
timeFrame: through study completion, an average of 1 year
measure: Number of relapses
timeFrame: through study completion, an average of 1 year
measure: Complete Remission
timeFrame: through study completion, an average of 1 year
measure: COVID-19 confirmed
timeFrame: From the date of leukemia diagnosis to the end of the induction chemotherapy cycle 1 (each cycle is 28 days)
Secondary outcomes:
Other outcomes:
Locations:
city: Ixtapaluca
country: Mexico
facility: Hospital Regional de Alta Especialidad de Ixtapaluca
state: State Of Mexico
city: Mexico City
country: Mexico
facility: Hospital General de México "Dr. Eduardo Liceaga"
Study officials:
References:
Clinical trial NCT03522116: Relationship Between CMR-derived Parameters of Ischemia / Reperfusion Injury and Timing of CMR in STEMI
Official title: Relationship Between CMR-derived Parameters of Ischemia / Reperfusion Injury and the Timing of CMR After Reperfused ST-segment Elevation Myocardial Infarction
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Myocardial Infarction
Lead sponsor: Centre Hospitalier Universitaire Vaudois
Sponsor class: OTHER
First posted: 2018-05-11
Enrollment: 220
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Consecutive patients admitted to Lausanne University Hospital with the diagnosis of STEMI

Brief summary: This a prospective observational study including patients with ST-segment elevation myocardial infarction undergoing cardiovascular magnetic resonance for clinical reason during the index hospitalization. This local registry stemmed from multi-center european registry on cardiovascular magnetic resonance


Eligibility criteria: Inclusion Criteria:

* Diagnosis of STEMI
* Undergoing CMR during the index hospitalization

Exclusion Criteria:

* Refractory cardiogenic shock
* claustrophobia
* eGFR\<30 ml/min/1.73m2

Primary outcomes:
measure: Metrics of ischemia / repercussion injury
timeFrame: June 2017
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT04406116: Clinical Evaluation of the Safety and Performance of Microwave Coagulation Using the HS1 Instrument
Official title: Clinical Evaluation of the Safety and Performance of Microwave Coagulation Using the HS1 Instrument for Actual or Potential Non-variceal Bleeding in the Upper Gastrointestinal (GI) Tract
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Actual or Potential Nonvariceal Bleeding in the Upper Gastrointestinal (GI) Tract
Lead sponsor: Creo Medical Limited
Sponsor class: INDUSTRY
First posted: 2020-05-28
Enrollment: 35
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: Clinical evaluation of the safety and performance of microwave coagulation using the HS1 Instrument for actual or potential non-variceal bleeding in the upper Gastrointestinal (GI) tract


Eligibility criteria: Inclusion Criteria:

* Patient or authorised representative able to comprehend and sign the Informed Consent form.
* Actual or potential non-variceal bleeding in the upper GI, including angiodysplasia or AVM malformations such as Dieulafoy's lesion with a Glasgow-Blatchford score of greater than 1

Exclusion Criteria:

* As stated in the contraindications in the HS1 IFU;
* Aged \<18 years of age
* Those described as vulnerable populations in EN ISO 14155;
* Patients with a known coagulopathy (congenital);
* Concurrent participation in another experimental intervention or drug study
* Unwilling or unable to provide informed consent.
* A patient whose Glasgow-Blatchford score is 1 or less

Primary outcomes:
measure: Effective coagulation of of actual or potential non-variceal bleeding in the upper Gastrointestinal (GI) tract.
timeFrame: Perioperative
Secondary outcomes:
measure: Identification and incidence of intra-procedural complications
timeFrame: Day 0
measure: Identification and incidence of post-procedural complications
timeFrame: At 24-72 hours, 1 week and 4 weeks
measure: Change in Glasgow-Blatchford score
timeFrame: Day 0 for initial screen and then 24-72 hours post-procedure for second score.
Other outcomes:
measure: Questionnaire assessment of device injection features
timeFrame: Perioperative
measure: Questionnaire assessment of device adhesion characteristics
timeFrame: Perioperative
Locations:
city: Canterbury
country: United Kingdom
facility: East Kent Hospitals University Nhs Foundation Trust
state: Kent
Study officials:
References:
Clinical trial NCT00604916: Oral Care Protocol for Preventing Ventilator- Associated Pneumonia
Official title: The Effectiveness of an Oral Care Protocol in Preventing Ventilator- Associated Pneumonia for Intensive Care Unit Patient
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: EARLY_PHASE1
Conditions: Pneumonia
Keywords: oral hygiene
Lead sponsor: Mackay Memorial Hospital
Sponsor class: OTHER
Collaborators: name: National Taiwan University
First posted: 2008-01-30
Enrollment: 53
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: The Nosocomial Pneumonia remains to be a major complication for patients who were incubated with ventilation. Most cases are attributed to increased bacteria flora in oropharyngeal secretion and aspiration of those organisms. Research indicates that the Gram-Negative Bacteria grows in upper air way and trachea rapidly during the initial 2-4 hospital days and the dental plague also increased dramatically at the first 5 days. About 50% cases with prolonged intubation experienced temporal swallowing disorders and majority of them recovered 7 days post weaning. Some evidence exist suggesting that oral care could reduce bacterial flora, prevent aspiration, and subsequently decrease the incidence of ventilation-associated pneumonia for this group of high risk patients.

This study aims to evaluate the effectiveness of a standardized oral care protocol in improving oral hygiene and reducing the incidence of pneumonia on a sample of surgical patients at intensive care unit.


Eligibility criteria: Inclusion Criteria:

* Patients newly admitted to SICU who were under ventilator support for 48\~72 hours

Exclusion Criteria:

* With pneumonia present

Primary outcomes:
measure: the oral hygiene status measured by the oral assessment guide and plague index
timeFrame: every 3~4days
Secondary outcomes:
measure: The incidence of VAP defined by the Clinical Pulmonary Infection Score
timeFrame: a 7 day oral care protocol duration
Other outcomes:
Locations:
Study officials:
affiliation: School of Nursing, National Taiwan University
name: li-yin YAO, BSN
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05472116: Capillary Refill Time Measurement Utilizing Mobile Application in Children
Official title: Capillary Refill Time Measurement Utilizing Mobile Application in Children
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Healthy Children (1 Month to 17 Years Old)
Keywords: Capillary Refill
Mobile Health Application
Pediatrics
Lead sponsor: University of Minnesota
Sponsor class: OTHER
First posted: 2022-07-25
Enrollment: 193
Sex: ALL
Minimum age (years): 1
Maximum age (years): 17
Standard ages: CHILD
Accepts healthy volunteers: yes
Observational model: CASE_CONTROL
Time perspective: CROSS_SECTIONAL
Sampling method: PROBABILITY_SAMPLE
Study population: Healthy children age 1 month to 17 years

Brief summary: To determine the accuracy and precision of capillary refill time measurement using a mobile health application (Cap App) in a healthy pediatric population. This will be a cross-sectional study measuring the capillary refill time in a healthy pediatric population using both the Cap App and two additional manual methods which will serve as the comparison.


Eligibility criteria: Inclusion Criteria:

* Healthy children aged 1 month to 17 years

Exclusion Criteria:

* Fever or hypothermia
* Chronic illness including cardiovascular or renal disease
* Severe injury or blood loss
* Dehydration
* Raynaud's phenomenon

Primary outcomes:
measure: Accuracy and Precision of a Mobile Health Application (Cap App)
timeFrame: Time it takes for blood to return to issue on the fingertip after pressure application for 5 seconds
Secondary outcomes:
Other outcomes:
Locations:
city: Minneapolis
country: United States
facility: University of Minnesota
state: Minnesota
Study officials:
References:
Clinical trial NCT01563016: Glucose as a Mediator of Self-control Performances in Patients With Schizophrenia
Official title: Glucose as a Mediator of Self-control Performances in Patients With Schizophrenia: A Randomized Controlled Study
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Schizophrenia
Keywords: schizophrenia
Psychotic Disorders
Psychoses
Lead sponsor: The University of Hong Kong
Sponsor class: OTHER
Collaborators: name: Queen Mary Hospital, Hong Kong
First posted: 2012-03-26
Enrollment: 100
Sex: ALL
Minimum age (years): 15
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The research aims to investigate the relationship between self-control ability and blood glucose level in schizophrenic patients. The main purpose of the present study is to explore whether the close relationship of blood glucose and self-regulatory strength observed in healthy individuals, is applicable to schizophrenic patients. More specifically, the current study aims

* to investigate whether the exertion of self-control reduces blood glucose,
* to examine whether low level of blood glucose deteriorates subsequent self-control performances
* to examine whether restoring the glucose level eliminates these impairments, in schizophrenic patients.


Eligibility criteria: Inclusion Criteria:

* Aged 15 or above
* DSM-IV diagnosis of schizophrenia, schizoaffective disorder, schizophreniform psychosis, brief psychosis, psychosis NOS or delusional disorder
* Cantonese-speaking Chinese
* Ability to understand the nature of the study and sign informed consent

Exclusion Criteria:

* Organic Brain disorder
* Known history of intellectual disability
* Priority Follow Up (Subtarget or Target)
* All allergic to any sugar or artificial sweeteners
* Diabetics
* Physical Disability

Primary outcomes:
measure: Blood Glucose Level
timeFrame: baseline, after depleting task
measure: self control tasks (handgrip, stroop, figure tracing task)
timeFrame: after 12-minutes metabolizing phase
Secondary outcomes:
Other outcomes:
Locations:
city: Hong Kong
country: China
facility: The University of Hong Kong
Study officials:
affiliation: The University of Hong Kong
name: Eric YH Chen, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00229216: Treatment of Bacterial Vaginosis With Oral Tinidazole
Official title: A Phase III Randomized, Multi-center, Double-blind, Double-dummy, Placebo-controlled Treatment Trial of Bacterial Vaginosis With Tinidazole Oral Tablets.
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Bacterial Vaginosis
Lead sponsor: Mission Pharmacal
Sponsor class: INDUSTRY
First posted: 2005-09-29
Enrollment: 200
Sex: FEMALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to confirm the safety and efficacy of oral tinidazole for the treatment of bacterial vaginosis.

Detailed description: Tinidazole is a second-generation nitroimidazole i.e. an updated form of the standard drug used to treat bacterial vaginosis (metronidazole). Two dosing regimens are being compared to placebo to treat bacterial vaginosis, one of the most common vaginal infections.

Eligibility criteria: Inclusion Criteria:

Clinical and microbiological diagnosis of bacterial vaginosis -

Exclusion Criteria:

Other sexually transmitted disease

-

Primary outcomes:
measure: Therapeutic efficacy
measure: Safety
Secondary outcomes:
measure: Clinical efficacy
measure: Microbiological efficacy
Other outcomes:
Locations:
city: Durham
country: United States
facility: Duke University School of Medicine
state: North Carolina
Study officials:
References:
citation: Livengood CH 3rd, Ferris DG, Wiesenfeld HC, Hillier SL, Soper DE, Nyirjesy P, Marrazzo J, Chatwani A, Fine P, Sobel J, Taylor SN, Wood L, Kanalas JJ. Effectiveness of two tinidazole regimens in treatment of bacterial vaginosis: a randomized controlled trial. Obstet Gynecol. 2007 Aug;110(2 Pt 1):302-9. doi: 10.1097/01.AOG.0000275282.60506.3d.
Clinical trial NCT04536116: Virtual Reality As Anxiety Management Tool for Preparing Children for MR Exam
Official title: EvaLuation De L'apport De L'Irm Virtuelle Sur La Qualité De La Prise En Charge Des Enfants En Irm
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Claustrophobia
Lead sponsor: Central Hospital, Nancy, France
Sponsor class: OTHER
First posted: 2020-09-02
Enrollment: 44
Sex: ALL
Minimum age (years): 6
Maximum age (years): 12
Standard ages: CHILD
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: OTHER

Brief summary: The access to MRI examination is limited due to the duration of the acquisitions, the noise and the narrow patient space of the device. A child can, therefore, be anxious, less cooperative and move more during the acquisition, affecting the quality of the examination and the medical diagnosis. General anesthesia or sedation, may be considered to obtain diagnostic quality examinations. Our hypothesis is that a scenario as close as possible to reality to prepare children before the MR exam could reduce their anxiety, improve the quality of the exams and reduce its duration.

The purpose of this study is to evaluate the effect of virtual reality on MRI exam preparation to reduce the anxiety of children (aged from 6 to 12 years) who are referred to their first MRI exam, as compared to the current practice.


Eligibility criteria: Inclusion Criteria:

* Child from 6 to 12 years old,
* Child who will have an MRI for the first time,
* Outpatient child,
* Child dependent on a parent affiliated to or beneficiary of a social security scheme,
* Child who has received age-appropriate information on the organization of the research,
* Child whose parents (or the only parent present with parental authority) have been fully informed about the organization of the research and have signed informed consent.

Exclusion Criteria:

* Conditions that not allow the realization of a virtual MRI sceanrio or not allow to respond the scales (epilepsy, mental disorders, language, ...),
* Child with a contraindication to performing an MRI,
* Child who has benefited from another MRI simulation system before ("IRM en Jeu" for instance)
* Child's opposition to participate.

Primary outcomes:
measure: Anxiety
timeFrame: 2 hours
Secondary outcomes:
Other outcomes:
Locations:
city: Vandoeuvre les nancy
country: France
facility: CHRU de Nancy
Study officials:
affiliation: CHRU de Nancy
name: Coralie SERVAIT, PI
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02799316: Is Hepatitis B Surface Antigen (HB s Ag) Enough Alone as a Screening Test Before Immunosuppressive Therapies?
Official title: Is Hepatitis B Surface Antigen (HB s Ag) Enough Alone as a Screening Test for Hepatitis B Virus Infection in Rheumatic Disease Patients Before Starting Immunosuppressive Therapies??
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Hepatitis B
Lead sponsor: Tanta University
Sponsor class: OTHER
First posted: 2016-06-14
Enrollment: 100
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: DIAGNOSTIC

Brief summary: Hepatitis B virus (HBV) infection is a challenging health problem. According to the World Health Organization, an estimated 240 million individuals (3.7%) suffered from chronic HBV infection worldwide.

After acute hepatitis B virus (HBV) infection, the disappearance of hepatitis B surface antigen (HBsAg) had generally been believed to signify viral elimination. However, it now becomes clear that those subjects may have occult HBV infection which is defined as the presence of HBV DNA in the liver in the absence of HBsAg in the serum. Occult HBV infection usually accompanies antibody against hepatitis B core antigen (anti-HBc) and/or antibody against HBsAg (anti-HBs), but some cases might not have these serological markers (seronegative occult HBV infection) .

Detailed description: In a recent systematic review, nearly 40% of HBsAg carriers and 5% of antiHBc-positive but HBsAg-negative patients developed HBVr during TNF inhibitor therapy.

Considering the lifelong use of multiple antirheumatic drugs, we need more specific guidelines for the management of rheumatic disease patients who are scheduled to receive biological and/or non-biological DMARDs.

Eligibility criteria: Inclusion Criteria:

* • Any patients with rheumatic disease with hepatitis B surface antigen negative.

Exclusion Criteria:

* • Overt co-morbid condition.

  * Any malignancy e.g. HCC

Primary outcomes:
measure: Number of patients with occult HBV.
timeFrame: 1 year
Secondary outcomes:
Other outcomes:
Locations:
city: Cairo
country: Egypt
facility: Sherief Abd-Elsalam
Study officials:
affiliation: Internal medicine department - Tanta university
name: Rasha A Abdel Noor, Consultant
role: PRINCIPAL_INVESTIGATOR
affiliation: Division of Gastroenterology and Hepatology- Tanta
name: Sherief Abd-Elsalam, Consultant
role: STUDY_CHAIR
affiliation: liver diseases dept.-Tanta university hospital
name: Walaa Elkhalawany, Consultant
role: STUDY_CHAIR
affiliation: liver diseases dept.-Tanta university hospital
name: Mona Watani, Consultant
role: STUDY_CHAIR
affiliation: liver diseases dept.-Tanta university hospital
name: Rehab Badawi, Consultant
role: STUDY_CHAIR
References:
Clinical trial NCT06841016: Virtual Nephrologist Pilot
Official title: An Interactive, Conversational Virtual Healthcare Agent to Educate and Engage Patients With Advanced Chronic Kidney Disease About Transplantation (Part 2: Pilot)
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Chronic Kidney Disease(CKD)
Keywords: CKD
transplantation
virtual healthcare agent
NKF
Lead sponsor: University of Pennsylvania
Sponsor class: OTHER
Collaborators: name: University of Florida
First posted: 2025-02-21
Enrollment: 200
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: DIAGNOSTIC

Brief summary: To develop, pilot, and refine a virtual healthcare agent that will educate patients with advanced chronic kidney disease and their caregivers about kidney transplantation.

Detailed description: Over 35 million Americans endure the burdens of chronic kidney disease (CKD). Black Americans face particularly high rates of CKD due to environmental and genetic factors, including systemic racism and inadequate access to specialty providers and effective therapies. The optimal management of advanced CKD poses many challenges for patients, especially those with low health literacy, because of the complexity of medical management and treatment options. For many patients with advanced CKD, pursuing kidney transplantation has major advantages. Compared to chronic dialysis, kidney transplantation improves quality of life and length of life, and offers greater capacity to participate in important activities such as employment. Unfortunately, many patients do not gain sufficient information about kidney transplant or have misconceptions and fears about transplant. This knowledge gap exists in part because many patients have limited access to nephrology care and due to time constraints and ineffective education during nephrology visits. New media technologies can address this need by enabling patients to interact with a virtual health care assistant that both empowers patients to direct the communication toward their own information needs and communicates with patients using language and norms that are comfortable. We will develop a virtual healthcare assistant to interact with, educate and counsel patients and their caregivers about kidney transplantation. The tool will provide content developed by the National Kidney Foundation, the leading patient-facing organization focused on kidney disease. Informed by patient partnerships, the tool will address in particular the needs and concerns of Black Americans with kidney disease.

Eligibility criteria: Inclusion Criteria:

* 18 y/o able to provide consent
* Advanced CKD
* English speaking
* Penn Medicine patient

Exclusion Criteria:

* Vulnerable populations

Primary outcomes:
measure: Median change in Transplant intention Likert scale question from pre- to post-vHCA
timeFrame: 1 year
Secondary outcomes:
Other outcomes:
Locations:
city: Philadelphia
country: United States
facility: Hospital of the University of Pennsylvania
state: Pennsylvania
Study officials:
References: